Durect Corp Sustainability Reports
DURECT Corporation is a biopharmaceutical company focused on developing epigenetic regulator therapies. Its primary pipeline candidate is larsucosterol, which targets serious conditions such as alcohol-associated hepatitis.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG001SG3GG5
6 reports from 2008 to 2022
Company Profile
DURECT Corporation is a biopharmaceutical company focused on developing epigenetic regulator therapies. Its primary pipeline candidate is larsucosterol, which targets serious conditions such as alcohol-associated hepatitis.
Reports
6 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
